

# Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Resected Non-Small-Cell Lung Cancers: American Society of Clinical Oncology and Canadian Society of Radiation Oncology Care Ontario Clinical Practice Guideline Update

Journal of Clinical Oncology

35, 2960-2974

DOI: 10.1200/jco.2017.72.4401

Citation Report

#	ARTICLE	IF	CITATIONS
1	Liquid biopsy for ctDNA to revolutionize the care of patients with early stage lung cancers. <i>Annals of Translational Medicine</i> , 2017, 5, 479-479.	1.7	11
2	What is the optimal adjuvant therapy for T3N0 lung cancer invading the chest wall?. <i>Journal of Thoracic Disease</i> , 2017, 9, 4233-4235.	1.4	0
3	Circulating tumor DNA: A promising biomarker to guide postoperative treatment and surveillance of nonâ€‘small cell lung cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2018, 155, 2628-2631.	0.8	10
4	Early Mortality in Patients Undergoing Adjuvant Chemotherapy for Nonâ€‘Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 543-549.	1.1	15
5	The biology and management of non-small cell lung cancer. <i>Nature</i> , 2018, 553, 446-454.	27.8	2,877
6	One size does not fit all: Nuances in postoperative N2â€‘nonâ€‘small cell lung cancer management. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2018, 156, 370-373.	0.8	2
7	Long nonâ€‘coding RNA linc01433 promotes migration and invasion in nonâ€‘small cell lung cancer. <i>Thoracic Cancer</i> , 2018, 9, 589-597.	1.9	19
8	Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage IIâ€‘IIIa (N1â€‘N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. <i>Lancet Oncology</i> , The, 2018, 19, 139-148.	10.7	436
9	Stereotactic Body Radiotherapy for Early-Stage Nonâ€‘Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American Society for Radiation Oncology Evidence-Based Guideline. <i>Journal of Clinical Oncology</i> , 2018, 36, 710-719.	1.6	127
10	Liquid biopsy for lung cancer early detection. <i>Journal of Thoracic Disease</i> , 2018, 10, S882-S897.	1.4	93
11	Meet the new boss: lung cancer staging. <i>Journal of Thoracic Disease</i> , 2018, 10, 1329-1331.	1.4	1
12	Adjuvant EGFR TKI therapy for resectable non-small cell lung cancer: new era for personalized medicine. <i>Journal of Thoracic Disease</i> , 2018, 10, 1364-1369.	1.4	6
13	Invited letter to the editor on the editorial on â€‘Clinical staging of NSCLC: current evidence and implications for adjuvant chemotherapyâ€™. <i>Journal of Thoracic Disease</i> , 2018, 10, S2083-S2085.	1.4	1
14	Post-operative radiation therapy in locally advanced non-small cell lung cancer and the impact of sequential versus concurrent chemotherapy. <i>Translational Lung Cancer Research</i> , 2018, 7, S171-S175.	2.8	1
15	Epidermal growth factor receptor inhibitors in adjuvant treatment of lung cancerâ€‘the more specific, the better?. <i>Journal of Thoracic Disease</i> , 2018, 10, S3961-S3964.	1.4	1
16	The relationship between the expression of thymidylate synthase, dihydropyrimidine dehydrogenase, orotate phosphoribosyltransferase, excision repair crossâ€‘complementation group 1 and class III Î²â€‘tubulin, and the therapeutic effect of Sâ€‘1 or carboplatin plus paclitaxel in nonâ€‘smallâ€‘cell lung cancer. <i>Molecular and Clinical Oncology</i> , 2018, 9, 21-29.	1.0	3
17	Research progress of the clinicopathologic features of lung adenosquamous carcinoma. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 7011-7017.	2.0	12
18	Link between tumor-promoting fibrous microenvironment and an immunosuppressive microenvironment in stage I lung adenocarcinoma. <i>Lung Cancer</i> , 2018, 126, 64-71.	2.0	39

#	ARTICLE	IF	CITATIONS
19	The lymph node status and histologic subtypes influenced the effect of postoperative radiotherapy on patients with N2 positive IIIA nonâ€‘small cell lung cancer. Journal of Surgical Oncology, 2019, 119, 379-387.	1.7	26
20	Altered editing level of microRNAs is a potential biomarker in lung adenocarcinoma. Cancer Science, 2018, 109, 3326-3335.	3.9	32
21	Adenosquamous carcinoma of the lung. OncoTargets and Therapy, 2018, Volume 11, 4829-4835.	2.0	70
22	What pharmacotherapeutics should one use for early stage non-small cell lung cancer?. Expert Opinion on Pharmacotherapy, 2018, 19, 1403-1406.	1.8	4
23	Unsuspected N2-positive non-small cell lung cancer after complete resection: is there a place for multimodal adjuvant therapy?. AME Medical Journal, 0, 3, 23-23.	0.4	0
24	Gene Expression Signatures Predicting Survival and Chemotherapy Benefit in Patients with Resected Non-small-Cell Lung Cancer. EBioMedicine, 2018, 33, 16-17.	6.1	4
25	Preoperative radiation may improve the outcomes of resectable IIIA/N2 nonâ€‘smallâ€‘cell lung cancer patients: A propensity score matchingâ€‘based analysis from surveillance, epidemiology, and end results database. Cancer Medicine, 2018, 7, 4354-4360.	2.8	18
26	RANBP9 affects cancer cells response to genotoxic stress and its overexpression is associated with worse response to platinum in NSCLC patients. Oncogene, 2018, 37, 6463-6476.	5.9	15
27	A meta-analysis of adjuvant EGFR-TKIs for patients with resected non-small cell lung cancer. Lung Cancer, 2019, 137, 7-13.	2.0	36
28	Check the Reports and Check the Brain. International Journal of Radiation Oncology Biology Physics, 2019, 104, 711-712.	0.8	0
29	The Role of Adjuvant Radiotherapy for Resected Non-Small Cell Lung Cancer in the Modern Era. International Journal of Radiation Oncology Biology Physics, 2019, 104, 712-713.	0.8	0
30	KRAS Mutation for Staging Resected Nonâ€‘Small Cell Lung Cancer. Journal of Thoracic Oncology, 2019, 14, e153-e155.	1.1	2
31	Thoracic Postoperative Radiation Therapy: To Treat or Not to Treat?. International Journal of Radiation Oncology Biology Physics, 2019, 104, 710.	0.8	4
32	A Reactionâ€‘Based Fluorescent Probe for Imaging of Native Hypochlorous Acid. Chemistry - an Asian Journal, 2019, 14, 3893-3897.	3.3	13
33	Post-Surgery Circulating Tumor Cells and AXL Overexpression as New Poor Prognostic Biomarkers in Resected Lung Adenocarcinoma. Cancers, 2019, 11, 1750.	3.7	29
34	<p>&gt;Neutrophil-To-Lymphocyte Ratio Predicted Long-Term Chemotherapy Benefits In Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer Patients Without Sensitive Mutations</p>&gt;. OncoTargets and Therapy, 2019, Volume 12, 8779-8787.	2.0	5
35	Why Be One Protein When You Can Affect Many? The Multiple Roles of YB-1 in Lung Cancer and Mesothelioma. Frontiers in Cell and Developmental Biology, 2019, 7, 221.	3.7	26
36	Retrospective study of efficacy of adjuvant chemotherapy using tegafur-uracil in patients with non-small cell lung cancer with primary tumor size of 4.1â€‘5.0 cm. Journal of Thoracic Disease, 2019, 11, 3103-3111.	1.4	2

#	ARTICLE	IF	CITATIONS
37	Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer. JCO Precision Oncology, 2019, 3, 1-12.	3.0	24
38	Adjuvant Chemotherapy Improves Survival in Surgically Resected Stage IB Squamous Lung Cancer. Annals of Thoracic Surgery, 2019, 107, 1683-1689.	1.3	6
39	Adjuvant Chemotherapy Candidates in Stage I Lung Adenocarcinomas Following Complete Lobectomy. Annals of Surgical Oncology, 2019, 26, 2392-2400.	1.5	12
40	Propensity-matched analysis of adjuvant chemotherapy for completely resected Stage IB non-small-cell lung cancer patients. Lung Cancer, 2019, 133, 75-82.	2.0	21
41	<p>Differential effects of adjuvant EGFR tyrosine kinase inhibitors in patients with different stages of non-small-cell lung cancer after radical resection: an updated meta-analysis<p>. Cancer Management and Research, 2019, Volume 11, 2677-2690.	1.9	10
42	Circular RNAs and RNA Splice Variants as Biomarkers for Prognosis and Therapeutic Response in the Liquid Biopsies of Lung Cancer Patients. Frontiers in Genetics, 2019, 10, 390.	2.3	68
43	SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptorâ€“Mutant Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2019, 37, 97-104.	1.6	159
44	<p>miR-600 inhibits lung cancer via downregulating the expression of METTL3<p>. Cancer Management and Research, 2019, Volume 11, 1177-1187.	1.9	107
45	Interdisciplinary multimodality management of stage III nonsmall cell lung cancer. European Respiratory Review, 2019, 28, 190024.	7.1	47
46	<p>Low Expression of ASK1-Interacting Protein-1 Is Significantly Correlated with Tumor Angiogenesis and Poor Survival in Patients with Early Stage Non-Small Cell Lung Cancer<p>. OncoTargets and Therapy, 2019, Volume 12, 10739-10747.	2.0	1
47	Clinical characteristics and medical service utilization of lung cancer in China, 2005â€“2014: Overall design and results from a multicenter retrospective epidemiologic survey. Lung Cancer, 2019, 128, 91-100.	2.0	81
48	Procedure-Specific Risk Prediction for Recurrence in Patients Undergoing Lobectomy or Sublobar Resection for Small (â‰¤2 cm) Lung Adenocarcinoma: An International Cohort Analysis. Journal of Thoracic Oncology, 2019, 14, 72-86.	1.1	41
49	Collective cancer invasion forms an integrin-dependent radioresistant niche. Journal of Experimental Medicine, 2020, 217, .	8.5	55
50	Survival Prediction and Adjuvant Chemotherapy Based on Tumor Marker for Stage IB Lung Adenocarcinoma. Annals of Thoracic Surgery, 2020, 109, 927-937.	1.3	4
51	Novel prognostic model for stratifying survival in stage I lung adenocarcinoma patients. Journal of Cancer Research and Clinical Oncology, 2020, 146, 801-807.	2.5	9
52	Randomized phase II trial of adjuvant chemotherapy with docetaxel plus cisplatin versus paclitaxel plus carboplatin in patients with completely resected non-small cell lung cancer: TORC 0503. Lung Cancer, 2020, 141, 32-36.	2.0	9
53	Efficient Lung Nodule Classification Using Transferable Texture Convolutional Neural Network. IEEE Access, 2020, 8, 175859-175870.	4.2	41
54	Quality of life with adjuvant gefitinib versus vinorelbine plus cisplatin in patients with completely resected stage IIâ€“IIIA (N1â€“N2) EGFR-mutant non-small-cell lung cancer: Results from the ADJUVANT (CTONG1104) study. Lung Cancer, 2020, 150, 164-171.	2.0	5

#	ARTICLE	IF	CITATIONS
55	Clinical benefits of adjuvant chemotherapy with carboplatin and gemcitabine in patients with non-small cell lung cancer: a single-center retrospective study. <i>World Journal of Surgical Oncology</i> , 2020, 18, 263.	1.9	6
56	LncRNA CSMD1-1 promotes the progression of Hepatocellular Carcinoma by activating MYC signaling. <i>Theranostics</i> , 2020, 10, 7527-7544.	10.0	26
57	The Population-based Impact of Adjuvant Chemotherapy on Outcomes in T2N0M0 Non-Small Cell Lung Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 496-503.	1.3	2
58	Disparities in survival following surgery among patients with different histological types of N2-III non-small cell lung cancer: a Surveillance, Epidemiology and End Results (SEER) database analysis. <i>Annals of Translational Medicine</i> , 2020, 8, 1288-1288.	1.7	4
59	First-line treatment selection with organoids of an EGFRm + TP53m stage IA1 patient with early metastatic recurrence after radical surgery and follow-up. <i>Journal of Thoracic Disease</i> , 2020, 12, 3764-3773.	1.4	8
60	Management of screen-detected lung nodules: A Canadian partnership against cancer guidance document. <i>Canadian Journal of Respiratory, Critical Care, and Sleep Medicine</i> , 2020, 4, 236-265.	0.5	9
61	Association of Survival With Adjuvant Chemotherapy Among Patients With Early-Stage Non-Small Cell Lung Cancer With vs Without High-Risk Clinicopathologic Features. <i>JAMA Oncology</i> , 2020, 6, 1741.	7.1	55
62	Radiomics nomogram for prediction disease-free survival and adjuvant chemotherapy benefits in patients with resected stage I lung adenocarcinoma. <i>Translational Lung Cancer Research</i> , 2020, 9, 1112-1123.	2.8	27
63	Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2020, 383, 1711-1723.	27.0	1,042
64	ZIC2 promotes cancer stem cell traits via up-regulating OCT4 expression in lung adenocarcinoma cells. <i>Journal of Cancer</i> , 2020, 11, 6070-6080.	2.5	11
65	Risk Prediction for Locoregional Recurrence in Epidermal Growth Factor Receptor-Mutant Stage III-pN2 Lung Adenocarcinoma after Complete Resection: A Multi-center Retrospective Study. <i>Journal of Cancer</i> , 2020, 11, 6114-6121.	2.5	2
66	Striving toward Improved Outcomes for Surgically Resectable Non-Small Cell Lung Cancer: the Promise and Challenges of Neoadjuvant Immunotherapy. <i>Current Oncology Reports</i> , 2020, 22, 109.	4.0	10
67	Identification of a 4-lncRNA signature predicting prognosis of patients with non-small cell lung cancer: a multicenter study in China. <i>Journal of Translational Medicine</i> , 2020, 18, 320.	4.4	7
68	Thymosin $\beta$ 10 promotes tumor-associated macrophages M2 conversion and proliferation via the PI3K/Akt pathway in lung adenocarcinoma. <i>Respiratory Research</i> , 2020, 21, 328.	3.6	18
69	A phase III study of adjuvant chemotherapy in patients with completely resected, node-negative non-small cell lung cancer (JCOG 0707). <i>JTCVS Open</i> , 2020, 4, 90-102.	0.5	14
70	Stratification of Patients With Stage IB NSCLC Based on the 8th Edition of the American Joint Committee on Cancer (AJCC) Staging Manual. <i>Frontiers in Oncology</i> , 2020, 10, 571.	2.8	26
71	Comparative analysis of prognostic histopathologic parameters in subtypes of epithelioid pleural mesothelioma. <i>Histopathology</i> , 2020, 77, 55-66.	2.9	13
72	circ_0007385 served as competing endogenous RNA for miR-519d-3p to suppress malignant behaviors and cisplatin resistance of non-small cell lung cancer cells. <i>Thoracic Cancer</i> , 2020, 11, 2196-2208.	1.9	34

#	ARTICLE	IF	CITATIONS
73	Galgo: a bi-objective evolutionary meta-heuristic identifies robust transcriptomic classifiers associated with patient outcome across multiple cancer types. <i>Bioinformatics</i> , 2020, 36, 5037-5044.	4.1	1
74	Epigenetic therapy inhibits metastases by disrupting premetastatic niches. <i>Nature</i> , 2020, 579, 284-290.	27.8	213
75	Making Checkpoint Inhibitors Part of Treatment of Patients With Locally Advanced Lung Cancers: The Time Is Now. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, e159-e170.	3.8	7
76	A review on <scp>RNAi</scp> therapy for <scp>NSCLC</scp>: Opportunities and challenges. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2021, 13, e1677.	6.1	15
77	Management guidelines for stage III non-small cell lung cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103144.	4.4	17
78	Complementary and integrative medicine mention and recommendations: A systematic review and quality assessment of lung cancer clinical practice guidelines. <i>Integrative Medicine Research</i> , 2021, 10, 100452.	1.8	12
79	Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-III A (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 713-722.	1.6	159
80	Institutional-Level Differences in Quality and Outcomes of Lung Cancer Resections in the United States. <i>Chest</i> , 2021, 159, 1630-1641.	0.8	10
81	Influence of adjuvant chemotherapy on survival for patients with stage <scp>IB</scp> and <scp>IIA</scp> nonâ€small cell lung cancer. <i>Thoracic Cancer</i> , 2021, 12, 30-39.	1.9	13
82	Recent advances in early stage lung cancer. <i>Journal of Clinical and Translational Research</i> , 0, , .	0.3	4
83	Randomized Phase II Study of 3 Months or 2 Years of Adjuvant Afatinib in Patients With Surgically Resected Stage I-III <i>EGFR</i>-Mutant Nonâ€Small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 325-332.	3.0	7
84	Patient prognostic scores and association with survival improvement offered by postoperative radiotherapy for resected <scp>IIIA</scp>/<scp>N2</scp> nonâ€small cell lung cancer: A populationâ€based study. <i>Thoracic Cancer</i> , 2021, 12, 760-767.	1.9	8
85	Prognostic utility of inflammation-based biomarkers, neutrophilâ€lymphocyte ratio and change in neutrophilâ€lymphocyte ratio, in surgically resected lung cancers. <i>Annals of Thoracic Medicine</i> , 2021, 16, 148.	1.8	5
86	Endogenous glutamate determines ferroptosis sensitivity via ADCY10-dependent YAP suppression in lung adenocarcinoma. <i>Theranostics</i> , 2021, 11, 5650-5674.	10.0	76
87	Is It Time to Implement Adjuvant Targeted Therapy in EGFR-Mutant Nonâ€Small-Cell Lung Cancer?. <i>JCO Precision Oncology</i> , 2021, 5, 408-414.	3.0	7
88	Is Adjuvant Radiochemotherapy Always Mandatory in Patients with Resected N2 Non-Small Cell Lung Cancer?. <i>Thoracic and Cardiovascular Surgeon</i> , 2021, , .	1.0	0
89	Osimertinib in <i>EGFR</i>-Mutated Lung Cancer. <i>New England Journal of Medicine</i> , 2021, 384, 675-676.	27.0	8
90	Insights Into circRNAs: Functional Roles in Lung Cancer Management and the Potential Mechanisms. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 636913.	3.7	7

#	ARTICLE	IF	CITATIONS
91	Comprehensive Comparison Between Adjuvant Targeted Therapy and Chemotherapy for EGFR-Mutant NSCLC Patients: A Cost-Effectiveness Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 619376.	2.8	3
92	Real world duration of curative intent breast, colorectal, non-small cell lung, and prostate cancer treatment. <i>BMC Cancer</i> , 2021, 21, 215.	2.6	3
93	The role of <scp>EGFR&#x2013;TKIs</scp> as adjuvant therapy in <scp>EGFR mutation&#x2013;positive early&#x2013;stage NSCLC</scp>: A meta&#x2013;analysis. <i>Thoracic Cancer</i> , 2021, 12, 1084-1095.	1.9	12
94	Adjuvant Chemotherapy for T4 Non-Small Cell Lung Cancer with Additional Ipsilateral Lung Nodules. <i>Annals of Thoracic Surgery</i> , 2021, , .	1.3	2
95	Ferroptosis inducer erastin sensitizes NSCLC cells to celastrol through activation of the ROS&#x2013;mitochondrial fission&#x2013;mitophagy axis. <i>Molecular Oncology</i> , 2021, 15, 2084-2105.	4.6	76
96	Impact of a Lymph Node Specimen Collection Kit on the Distribution and Survival Implications of the Proposed Revised Lung Cancer Residual Disease Classification: A Propensity-Matched Analysis. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100161.	1.1	2
97	Prognostic impact of extranodal extension in patients with pN1&#x2013;N2 lung adenocarcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 3699-3707.	2.5	6
98	Outcomes in 36 Patients with Stage IIIA-N2 Squamous Cell Carcinoma of the Lung Treated with Nab-Paclitaxel Plus Carboplatin as Neoadjuvant Therapy: A Prospective Study from a Single Center. <i>Medical Science Monitor</i> , 2021, 27, e930738.	1.1	5
99	Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 1165-1184.	1.6	54
100	Validation of the T Descriptor (TNM-8) in T3N0 Non-Small-Cell Lung Cancer Patients; a Bicentric Cohort Analysis with Arguments for Redefinition. <i>Cancers</i> , 2021, 13, 1812.	3.7	1
101	Drug Regimen for Patients after a Pneumonectomy. <i>Journal of Respiration</i> , 2021, 1, 114-134.	1.1	0
102	Evolution of systemic therapy for stages I&#x2013;III non-metastatic non-small-cell lung cancer. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 547-557.	27.6	152
103	New developments in locally advanced nonsmall cell lung cancer. <i>European Respiratory Review</i> , 2021, 30, 200227.	7.1	9
104	Comparative Effectiveness of a Lymph Node Collection Kit Versus Heightened Awareness on Lung Cancer Surgery Quality and Outcomes. <i>Journal of Thoracic Oncology</i> , 2021, 16, 774-783.	1.1	10
105	Lung cancer organoids analyzed on microwell arrays predict drug responses of patients within a week. <i>Nature Communications</i> , 2021, 12, 2581.	12.8	103
106	A novel CXCR4 antagonist counteracts paradoxical generation of cisplatin-induced pro-metastatic niches in lung cancer. <i>Molecular Therapy</i> , 2021, 29, 2963-2978.	8.2	9
107	Circulating CD15 <sup>+</sup> LOX&#x2013;1 <sup>+</sup> PMN&#x2013;MDSCs are a potential biomarker for the early diagnosis of non&#x2013;small&#x2013;cell lung cancer. <i>International Journal of Clinical Practice</i> , 2021, 75, e14317.	1.7	4
108	A comparison on the use of Perlin-noise and Gaussian noise based augmentation on X-ray classification of lung cancer patient. <i>Journal of Physics: Conference Series</i> , 2021, 1951, 012064.	0.4	5



#	ARTICLE	IF	CITATIONS
109	Immunotherapy and Vaccination in Surgically Resectable Non-Small Cell Lung Cancer (NSCLC). Vaccines, 2021, 9, 689.	4.4	9
110	Nomogram to Predict Cancer Specific Survival in Patients with Pathological Stage IA Non-small Cell Lung Cancer. Seminars in Thoracic and Cardiovascular Surgery, 2022, 34, 1040-1048.	0.6	8
111	Detection of Tumor Recurrence via Circulating Tumor DNA Profiling in Patients with Localized Lung Cancer: Clinical Considerations and Challenges. Cancers, 2021, 13, 3759.	3.7	14
112	Commentary: Adjuvant therapy in resected T1 2N0 non-“small cell lung cancer: Surgeons should lead. Journal of Thoracic and Cardiovascular Surgery, 2021, , .	0.8	0
113	Overall Survival Analyses following Adjuvant Chemotherapy or Nonadjuvant Chemotherapy in Patients with Stage IB Non-Small-Cell Lung Cancer. Journal of Oncology, 2021, 2021, 1-10.	1.3	9
114	FDA Approval Summary: Osimertinib for Adjuvant Treatment of Surgically Resected Non-“Small Cell Lung Cancer, a Collaborative Project Orbis Review. Clinical Cancer Research, 2021, 27, 6638-6643.	7.0	35
115	Multi-disciplinary approach for the management of non-metastatic non-small cell lung cancer in the Middle East and Africa: Expert panel recommendations. Lung Cancer, 2021, 158, 60-73.	2.0	6
116	The modification of T description according to visceral pleural invasion and tumor size from 3.1â€cm to 4.0â€cm in non-small cell lung cancer: A retrospective analysis based on the SEER database. Lung Cancer, 2021, 158, 47-54.	2.0	7
117	Association of postoperative recurrence with radiological and clinicopathological features in patients with stage IA-“IIA lung adenocarcinoma. European Journal of Radiology, 2021, 141, 109802.	2.6	2
118	Modification of Pathologic T Classification for Non-small Cell Lung Cancer With Visceral Pleural Invasion. Chest, 2021, 160, 754-764.	0.8	13
119	Development of Nomograms for Predicting Lymph Node Metastasis and Distant Metastasis in Newly Diagnosed T1-2 Non-Small Cell Lung Cancer: A Population-Based Analysis. Frontiers in Oncology, 2021, 11, 683282.	2.8	8
120	Identification of Key Genes Related to CD8+ T-Cell Infiltration as Prognostic Biomarkers for Lung Adenocarcinoma. Frontiers in Oncology, 2021, 11, 693353.	2.8	6
121	Molecular testing in stage I-“III non-small cell lung cancer: Approaches and challenges. Lung Cancer, 2021, 162, 42-53.	2.0	22
122	Effects of postoperative radiotherapy on cardiovascular-pulmonary disease mortality in patients with stage IIIA-N2 resected NSCLC: analysis of the SEER database. Radiation Oncology, 2021, 16, 184.	2.7	2
123	Antitumor efficacy of XPO1 inhibitor Selinexor in KRAS-mutant lung adenocarcinoma patient-derived xenografts. Translational Oncology, 2021, 14, 101179.	3.7	11
124	The effect that pathologic and radiologic interpretation of invasive and non-invasive areas in lung adenocarcinoma has on T-stage and treatment. Annals of Diagnostic Pathology, 2021, 54, 151799.	1.3	2
125	Trends in Accuracy and Comprehensiveness of Pathology Reports for Resected NSCLC in a High Mortality Area of the United States. Journal of Thoracic Oncology, 2021, 16, 1663-1671.	1.1	7
126	A predictive model for identifying candidates for adjuvant chemotherapy based on recurrence risk profile of resected, node-negative (N0) non-small cell lung cancer. Journal of Thoracic Disease, 2021, 13, 149-159.	1.4	1



#	ARTICLE	IF	CITATIONS
127	Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in the Adjuvant Setting for Patients with Resected Epidermal Growth Factor Receptor Mutant Non-Small Cell Lung Cancer: A Meta-Analysis with 11 Trials. <i>Oncology Research and Treatment</i> , 2021, 44, 344-353.	1.2	7
128	Inhibition of MGMT-mediated autophagy suppression decreases cisplatin chemosensitivity in gastric cancer. <i>Biomedicine and Pharmacotherapy</i> , 2020, 125, 109896.	5.6	28
129	Advances in the Treatment of Stage III Non-Small Cell Lung Cancer. <i>Clinics in Chest Medicine</i> , 2020, 41, 211-222.	2.1	18
130	Could tumor spread through air spaces benefit from adjuvant chemotherapy in stage I lung adenocarcinoma? A multi-institutional study. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592097814.	3.2	26
131	Receptor-interacting protein kinase 3 as a predictive adjuvant chemotherapy marker after lung adenocarcinoma resection. <i>Annals of Translational Medicine</i> , 2019, 7, 42-42.	1.7	9
132	Construction of a competing endogenous RNA network using differentially expressed lncRNAs, miRNAs and mRNAs in non-small cell lung cancer. <i>Oncology Reports</i> , 2019, 42, 2402-2415.	2.6	16
133	Saudi lung cancer management guidelines 2017. <i>Annals of Thoracic Medicine</i> , 2017, 12, 221.	1.8	16
134	Effects of Postoperative Radiotherapy on Survival of Patients With Stage IIIA Resected Non-Small Cell Lung Cancer: Analysis of the SEER Database. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 718-727.	4.9	19
135	Durvalumab as Consolidation Therapy in Post-Concurrent Chemoradiation (CCRT) in Unresectable Stage III Non-Small Cell Lung Cancer Patients: A Multicenter Observational Study. <i>Vaccines</i> , 2021, 9, 1122.	4.4	18
136	Postoperative radiotherapy in resected non-small cell lung cancer: The never-ending story. <i>World Journal of Clinical Oncology</i> , 2021, 12, 833-844.	2.3	1
137	Role of Postoperative Radiotherapy in Patients With Completely Resected pIIIA-N2 Non-Small Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2022, 23, e171-e172.	2.6	1
140	A new method for accurately localizing and resecting pulmonary nodules. <i>Journal of Thoracic Disease</i> , 2020, 12, 4973-4984.	1.4	10
141	Optimizing adjuvant therapy in EGFR-mutated non-small cell lung cancer. <i>Annals of Translational Medicine</i> , 2020, 8, 1613-1613.	1.7	0
142	Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC. <i>Journal of Thoracic Oncology</i> , 2022, 17, 423-433.	1.1	89
144	Src-Homology 2 Domain-Containing Phosphatase 2 in Resected EGFR Mutation-Positive Lung Adenocarcinoma. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100084.	1.1	2
146	Recent advances in early stage lung cancer. <i>Journal of Clinical and Translational Research</i> , 2021, 7, 163-174.	0.3	4
147	Levels of pretreatment blood lipids are prognostic factors in advanced NSCLC patients treated with anlotinib. <i>Lipids in Health and Disease</i> , 2021, 20, 165.	3.0	6
148	Real-World Survival Outcomes Based on EGFR Mutation Status in Chinese Patients With Lung Adenocarcinoma After Complete Resection: Results From the ICAN Study. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100257.	1.1	11

#	ARTICLE	IF	CITATIONS
149	The dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110563.	3.2	6
150	Prognostic and predictive value of the newly proposed grading system of invasive pulmonary adenocarcinoma in Chinese patients: a retrospective multicohort study. <i>Modern Pathology</i> , 2022, 35, 749-756.	5.5	27
151	CDCP1 Expression Is a Potential Biomarker of Poor Prognosis in Resected Stage I Non-Small-Cell Lung Cancer. <i>Journal of Clinical Medicine</i> , 2022, 11, 341.	2.4	6
152	Indications and Parameters Around Postoperative Radiation Therapy for Lung Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 556-566.	1.6	17
153	Preoperative and Postoperative Systemic Therapy for Operable Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 546-555.	1.6	84
154	Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART, IFCT 0503): an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2022, 23, 104-114.	10.7	123
155	A nomogram to predict the recurrence-free survival and analyze the utility of chemotherapy in stage IB non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2022, 11, 75-86.	2.8	5
156	A potential biomarker based on clinical-radiomics nomogram for predicting survival and adjuvant chemotherapy benefit in resected node-negative, early-stage lung adenocarcinoma. <i>Journal of Thoracic Disease</i> , 2022, 14, 1-17.	1.4	0
157	BAP1 Downregulates NRF2 Target Genes and Exerts Anti-Tumorigenic Effects by Deubiquitinating KEAP1 in Lung Adenocarcinoma. <i>Antioxidants</i> , 2022, 11, 114.	5.1	3
158	Prognostic evaluation of the proposed residual tumor classification in a Chinese non-small cell lung cancer population. <i>Journal of Surgical Oncology</i> , 2022, 125, 1061-1070.	1.7	3
159	A randomised controlled trial of clinical pharmacy intervention versus standard care to improve medication adherence in outpatients with head and neck cancer receiving radiotherapy. <i>Supportive Care in Cancer</i> , 2022, 30, 4243-4253.	2.2	6
160	Cognitive adverse effects of chemotherapy and immunotherapy: are interventions within reach?. <i>Nature Reviews Neurology</i> , 2022, 18, 173-185.	10.1	31
161	Efficacy of adjuvant EGFR inhibitors and impact of clinical factors in resected EGFR-mutated non-small-cell lung cancer: a meta-analysis. <i>Future Oncology</i> , 2022, 18, 1159-1169.	2.4	6
162	Multidimensional profiling depicts infiltrating immune cell heterogeneity in the tumor microenvironment of stage IA non-small cell lung cancer. <i>Thoracic Cancer</i> , 2022, 13, 947-955.	1.9	8
163	Oncogenic Alterations in Histologically Negative Lymph Nodes Are Associated with Prognosis of Patients with Stage I Lung Adenocarcinoma. <i>Cancers</i> , 2022, 14, 824.	3.7	2
165	Adjuvant chemotherapy, extent of resection, and immunoistochemical neuroendocrine markers as prognostic factors of early-stage large-cell neuroendocrine carcinoma. <i>Thoracic Cancer</i> , 2022, 13, 900-912.	1.9	4
166	A Risk Model to Predict the Delivery of Adjuvant Chemotherapy Following Lung Resection in Patients With Pathologically Positive Lymph Nodes. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2023, 35, 387-398.	0.6	3
167	Efficacy and safety of adjuvant EGFR-TKIs for resected non-small cell lung cancer: a systematic review and meta-analysis based on randomized control trials. <i>BMC Cancer</i> , 2022, 22, 328.	2.6	16

#	ARTICLE	IF	CITATIONS
168	Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I-IIIA Completely Resected Non-Small-Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update. <i>Journal of Clinical Oncology</i> , 2022, 40, 1127-1129.	1.6	36
169	Use of adjuvant chemotherapy in resected non-small cell lung cancer in real-life practice: a systematic review of literature. <i>Translational Lung Cancer Research</i> , 2021, 10, 4643-4665.	2.8	7
170	The Independent Prognostic Effect of Lymph Node Dissection on Patients With Stage IA NSCLC With Different T Stages. <i>Frontiers in Surgery</i> , 2021, 8, 798046.	1.4	2
171	Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2022, 40, 1356-1384.	1.6	104
172	Extended resection for potentially operable patients with stage III non-small cell lung cancer after induction treatment. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2022, 164, 1587-1602.e5.	0.8	7
173	Analysis of Molecular Biomarkers in Resected Early-Stage Non-Small Cells Lung Cancer: A Narrative Review. <i>Cancers</i> , 2022, 14, 1949.	3.7	2
176	Immortal Time Bias-Corrected Effectiveness of Traditional Chinese Medicine in Non-Small Cell Lung Cancer (C-EVID): A Prospective Cohort Study. <i>Frontiers in Oncology</i> , 2022, 12, 845613.	2.8	3
177	Application of Non-Blood-Derived Fluid Biopsy in Monitoring Minimal Residual Diseases of Lung Cancer. <i>Frontiers in Surgery</i> , 2022, 9, .	1.4	3
178	Rethinking the Selection of Pathological T-Classification for Non-Small-Cell Lung Cancer in Varying Degrees of Visceral Pleural Invasion: A SEER-Based Study. <i>Frontiers in Surgery</i> , 2022, 9, .	1.4	2
179	Malignant Central Airway Obstruction: What's New?. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2022, 43, 512-529.	2.1	2
180	Osimertinib: A Review in Completely Resected, Early-Stage, EGFR Mutation-Positive NSCLC. <i>Targeted Oncology</i> , 2022, 17, 369-376.	3.6	4
181	A Real-World Systematic Analysis of Driver Mutations <sup>TM</sup> Prevalence in Early- and Advanced-Stage NSCLC: Implications for Targeted Therapies in the Adjuvant Setting. <i>Cancers</i> , 2022, 14, 2971.	3.7	6
182	Who are the real high-risk patients with pathological T2N0M0 non-small-cell lung cancer that can benefit from adjuvant chemotherapy?. <i>ESMO Open</i> , 2022, 7, 100508.	4.5	5
183	SEN1 Aberrance and Its Linkage to Clinical Features, Adjuvant Regimen, and Prognosis in Patients With Surgical Non-small Cell Lung Cancer Receiving Adjuvant Chemotherapy. <i>Frontiers in Surgery</i> , 0, 8, .	1.4	2
184	Adjuvant EGFR tyrosine kinase inhibitors for patients with resected EGFR-mutated non-small-cell lung cancer: a network meta-analysis. <i>Future Oncology</i> , 2022, 18, 2695-2707.	2.4	1
185	Cost-effectiveness of osimertinib versus placebo in resected EGFR-mutated non-small cell lung cancer in China. <i>Cancer Medicine</i> , 0, , .	2.8	2
186	Novel Inflammasome-Based Risk Score for Predicting Survival and Efficacy to Immunotherapy in Early-Stage Non-Small Cell Lung Cancer. <i>Biomedicines</i> , 2022, 10, 1539.	3.2	2
187	Method of Tissue Acquisition Affects Success of Comprehensive Genomic Profiling in Lung Cancer. <i>Archives of Pathology and Laboratory Medicine</i> , 2023, 147, 338-347.	2.5	2

#	ARTICLE	IF	CITATIONS
188	Camrelizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer: Treatment response, survival pattern, and safety. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2022, 47, 1775-1782.	1.5	2
189	Biomarkers and the microbiome in the detection and treatment of early-stage non-small cell lung cancer. <i>Seminars in Oncology</i> , 2022, 49, 285-297.	2.2	3
190	Real-world <sc>KINDLE</sc> Latin America subset data on treatment patterns and clinical outcomes in patients with stage <sc>III</sc> non-small cell lung cancer. <i>Cancer Medicine</i> , 0, , .	2.8	1
191	Host-Related Factors as Targetable Drivers of Immunotherapy Response in Non-Small Cell Lung Cancer Patients. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	6
192	Prognostic and predictive value of radiomic signature in stage I lung adenocarcinomas following complete lobectomy. <i>Journal of Translational Medicine</i> , 2022, 20, .	4.4	1
193	Adjuvant chemotherapy can benefit the survival of stage I lung adenocarcinoma patients with tumour spread through air spaces after resection: Propensity-score matched analysis. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	0
194	LIBRETTO-432, a phase III study of adjuvant selpercatinib or placebo in stage IB-IIIA <i>RET</i> fusion-positive non-small-cell lung cancer. <i>Future Oncology</i> , 2022, 18, 3133-3141.	2.4	9
195	Berberamine Hydrochloride inhibits lysosomal acidification by activating Nox2 to potentiate chemotherapy-induced apoptosis via the ROS-MAPK pathway in human lung carcinoma cells. <i>Cell Biology and Toxicology</i> , 2023, 39, 1297-1317.	5.3	4
196	EGFR mutation prevalence, real-world treatment patterns, and outcomes among patients with resected, early-stage, non-small cell lung cancer in Canada. <i>Lung Cancer</i> , 2022, 173, 58-66.	2.0	5
197	Egfr Mutation Prevalence, Real-World Treatment Patterns, and Outcomes Among Patients with Resected, Early-Stage, Non-Small Cell Lung Cancer in Canada. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
198	The effect of paclitaxel plus carboplatin chemotherapy on subclinical cardiotoxicity in patients with non-small cell lung cancer: A speckle tracking echocardiography-based study. <i>Revista Portuguesa De Cardiologia</i> , 2022, , .	0.5	3
200	Development and validation of a polygenic hazard score to predict prognosis and adjuvant chemotherapy benefit in early-stage non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2022, 11, 1809-1822.	2.8	0
202	LncRNA KCNQ1OT1 enhances the radioresistance of lung squamous cell carcinoma by targeting the miR-491-5p/TPX2-RNF2 axis. <i>Journal of Thoracic Disease</i> , 2022, 14, 4081-4095.	1.4	5
203	The Value of Radiotherapy in Patients With Resectable Stage IIIA Non-Small-Cell Lung Cancer in the Era of Individualized Treatment: A Population-Based Analysis. <i>Clinical Lung Cancer</i> , 2023, 24, 18-28.	2.6	2
204	A clinical risk model for assessing the survival of patients with stage IA-IIA non-small cell lung cancer after surgery. <i>Journal of Thoracic Disease</i> , 2022, 14, 4285-4296.	1.4	6
205	Adjuvant chemotherapy for completely resected IIA-IIIA non-small cell lung cancer: compliance to guidelines, safety and efficacy in real-life practice. <i>Translational Lung Cancer Research</i> , 2022, 11, 2418-2437.	2.8	2
206	Treatment Patterns and Outcomes in Resected Early-stage Non-small Cell Lung Cancer: An Analysis of the SEER-Medicare Data. <i>Clinical Lung Cancer</i> , 2023, 24, 260-268.	2.6	7
207	Potential Targets and Mechanisms of <i>Dalbergia odorifera</i> on Treating Lung Adenocarcinoma Explored by Network Pharmacology. <i>International Journal of Pharmacology</i> , 2023, 19, 52-63.	0.3	0

#	ARTICLE	IF	CITATIONS
208	Association between radiotherapy and risk of second primary malignancies in patients with resectable lung cancer: a population-based study. <i>Journal of Translational Medicine</i> , 2023, 21, .	4.4	2
209	Emerging precision neoadjuvant systemic therapy for patients with resectable non-small cell lung cancer: current status and perspectives. <i>Biomarker Research</i> , 2023, 11, .	6.8	8
210	CircRNA B cell linker regulates cisplatin sensitivity in nonsmall cell lung cancer via microRNA-25-3p/BarHä€like homeobox 2 axis. <i>Anti-Cancer Drugs</i> , 2023, 34, 640-651.	1.4	1
211	Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-III A Nonâ€Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial. <i>Journal of Clinical Oncology</i> , 2023, 41, 1830-1840.	1.6	84
212	Preoperative prognostic prediction for stage I lung adenocarcinomas: Impact of the computed tomography features associated with the new histological grading system. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	2
213	A new immune signature for survival prediction and immune checkpoint molecules in non-small cell lung cancer. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	2
214	Postoperative circulating tumor <scp>DNA</scp> can refine risk stratification in resectable lung cancer: results from a multicenter study. <i>Molecular Oncology</i> , 2023, 17, 825-838.	4.6	0
215	Adjuvant therapies in stages Iâ€III epidermal growth factor receptor-mutated lung cancer: current and future perspectives. <i>Translational Lung Cancer Research</i> , 2023, 12, 824-836.	2.8	2
216	Impact of surgery and adjuvant chemotherapy on the survival of stage I lung adenocarcinoma patients with tumor spread through air spaces. <i>Lung Cancer</i> , 2023, 177, 51-58.	2.0	4
217	Management of papillary thyroid cancer with tracheal invasion and lung cancer: A case report. <i>Oncology Letters</i> , 2023, 25, .	1.8	0
218	Adjuvant icotinib versus observation in patients with completely resected EGFR-mutated stage IB NSCLC (GASTO1003, CORIN): a randomised, open-label, phase 2 trial. <i>EClinicalMedicine</i> , 2023, 57, 101839.	7.1	7
219	Construction of IL-1 signalling pathway correlation model in lung adenocarcinoma and association with immune microenvironment prognosis and immunotherapy: Multi-data validation. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	0
220	Evaluation of Cost-Effectiveness of Adjuvant Osimertinib in Patients with Resected EGFR Mutation-Positive Non-small Cell Lung Cancer. <i>PharmacoEconomics - Open</i> , 0, , .	1.8	1
221	Surgically Treated pT2aN0M0 (Stage IB) Non-Small Cell Lung Cancer: A 20-Year Single-Center Retrospective Study. <i>Journal of Clinical Medicine</i> , 2023, 12, 2081.	2.4	0
222	Rapamycin Perfluorocarbon Nanoparticle Mitigates Cisplatin-Induced Acute Kidney Injury. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6086.	4.1	4
223	Postoperative chemotherapy significantly improves survival of elderly patients with stage <scp>IBâ€nonâ€small cell lung cancer: A populationâ€based study. <i>Cancer Medicine</i> , 2023, 12, 11254-11263.	2.8	2
224	Guidance for clinicians and patients with non-small cell lung cancer in the time of precision medicine. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	7
225	Multistageâ€Responsive Dualâ€Enzyme Nanocascades for Synergistic Radiosensitizationâ€Starvation Cancer Therapy. <i>Advanced Healthcare Materials</i> , 2023, 12, .	7.6	1

#	ARTICLE	IF	CITATIONS
226	Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC. <i>New England Journal of Medicine</i> , 2023, 389, 137-147.	27.0	106
227	Surgical Treatment Outcomes of Patients with Non-Small Cell Lung Cancer and Lymph Node Metastases. <i>Cancers</i> , 2023, 15, 3098.	3.7	0
228	The American Association for Thoracic Surgery (AATS) 2023 Expert Consensus Document: Staging and multidisciplinary management of patients with early-stage non-small cell lung cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2023, 166, 637-654.	0.8	8
229	Potential Applications of Nanoparticles in Improving the Outcome of Lung Cancer Treatment. <i>Genes</i> , 2023, 14, 1370.	2.4	4
230	B-Cell Infiltrate in the Tumor Microenvironment Is Associated With Improved Survival in Resected Lung Adenocarcinoma. <i>JTO Clinical and Research Reports</i> , 2023, 4, 100527.	1.1	0
231	Role of Olive Bioactive Compounds in Respiratory Diseases. <i>Antioxidants</i> , 2023, 12, 1140.	5.1	1
232	Outcomes and prognosis of non-small cell lung cancer patients who underwent curable surgery: a protocol for a real-world, retrospective, population-based and nationwide Chinese National Lung Cancer Cohort (CNLCC) study. <i>BMJ Open</i> , 2023, 13, e070188.	1.9	0
233	Clinical efficacy and safety of adjuvant EGFR-TKIs for resected stage IB lung adenocarcinoma: A real-world study based on propensity score matching. <i>Cancer Medicine</i> , 2023, 12, 18470-18478.	2.8	0
234	Research Progress of Traditional Chinese Medicine Combined with Chemotherapy in Non-Small Cell Lung Cancer. <i>Advances in Clinical Medicine</i> , 2023, 13, 13857-13862.	0.0	0
235	Targeted Therapies in Early-Stage Resectable Non-Small-Cell Lung Cancer: New Kids on the Block. <i>JCO Precision Oncology</i> , 2023, , .	3.0	0
236	Two Interventions on Pathologic Nodal Staging in a Population-Based Lung Cancer Resection Cohort. <i>Annals of Thoracic Surgery</i> , 2024, 117, 576-584.	1.3	1
237	Rational application of EGFR-TKI adjuvant therapy in patients with completely resected stage IB-IIIa EGFR-mutant NSCLC: a systematic review and meta-analysis of 11 randomized controlled trials. <i>BMC Cancer</i> , 2023, 23, .	2.6	0
238	A real-world study comparing perioperative chemotherapy and EGFR-tyrosine kinase inhibitors for treatment of resected stage III EGFR-mutant adenocarcinoma. <i>BMC Cancer</i> , 2023, 23, .	2.6	0
239	Exploring the past, present, and future of postoperative radiotherapy for N2 stage non-small cell lung cancer. <i>Radiation Oncology Journal</i> , 2023, 41, 144-153.	1.5	1
240	The impact of adjuvant EGFR-TKIs and 14-gene molecular assay on stage I non-small cell lung cancer with sensitive EGFR mutations. <i>EClinicalMedicine</i> , 2023, 64, 102205.	7.1	3
241	Economic burden of early-stage non-small-cell lung cancer: an assessment of healthcare resource utilization and medical costs. <i>Journal of Comparative Effectiveness Research</i> , 0, , .	1.4	0
242	Non-small-cell lung cancer with EGFR mutation in early stage. , 2023, , .		0
243	Regulation of Ferroptosis in Lung Adenocarcinoma. <i>International Journal of Molecular Sciences</i> , 2023, 24, 14614.	4.1	0



#	ARTICLE	IF	CITATIONS
244	TARGET: A Phase II, Open-Label, Single-Arm Study of 5-Year Adjuvant Osimertinib in Completely Resected EGFR-Mutated Stage IIâ€“IIIB NSCLC Post Complete Surgical Resection. <i>Clinical Lung Cancer</i> , 2023, , .	2.6	0
245	Treatment of Stage III Non-small Cell Lung Cancer. <i>Respiratory Medicine</i> , 2023, , 147-163.	0.1	0
246	Treatment of Early-Stage (Stage I and II) Non-Small Cell Lung Cancer. <i>Respiratory Medicine</i> , 2023, , 123-145.	0.1	0
247	Update on the Management of Stage III NSCLC: Navigating a Complex and Heterogeneous Stage of Disease. <i>Current Oncology</i> , 2023, 30, 9514-9529.	2.2	0
248	Understanding health-related quality of life measures used in early-stage non-small cell lung cancer clinical trials: A review. <i>Lung Cancer</i> , 2024, 187, 107419.	2.0	0
249	ERS International Congress 2023: highlights from the Thoracic Oncology Assembly. <i>ERJ Open Research</i> , 2024, 10, 00860-2023.	2.6	0
250	Adjuvant Osimertinib in Patients With Stage IB to IIIA EGFR Mutation-Positive NSCLC After Complete Tumor Resection: ADAURA China Subgroup Analysis. <i>JTO Clinical and Research Reports</i> , 2024, 5, 100621.	1.1	0
251	Impact of preoperative [18F]FDG PET/CT vs. contrast-enhanced CT in the staging and survival of patients with clinical stage I and II non-small cell lung cancer: a 10-year follow-up study. <i>Annals of Nuclear Medicine</i> , 2024, 38, 188-198.	2.2	0
252	Prognostic impact of adjuvant therapy for cisplatin-unfit patients with non-small-cell lung cancer: A multicenter analysis. <i>Lung Cancer</i> , 2024, 188, 107470.	2.0	0
253	Adjuvant and neo-adjuvant therapy for non-small cell lung cancer without EGFR mutations or ALK rearrangements. <i>International Journal of Clinical Oncology</i> , 0, , .	2.2	0
254	Circulating microRNA Panel for Prediction of Recurrence and Survival in Early-Stage Lung Adenocarcinoma. <i>International Journal of Molecular Sciences</i> , 2024, 25, 2331.	4.1	0
255	Who benefit from adjuvant chemotherapy in stage I lung adenocarcinoma? A multi-dimensional model for candidate selection. <i>Neoplasia</i> , 2024, 50, 100979.	5.3	0
256	Survival benefit of adjuvant chemotherapy after resection of Stage I lung adenocarcinoma containing micropapillary components. <i>Cancer Medicine</i> , 2024, 13, .	2.8	0
257	Beneficial implications of adjuvant chemotherapy for stage IB lung adenocarcinoma exhibiting elevated SUVmax in FDG-PET/CT: a retrospective study from a single center. <i>Frontiers in Oncology</i> , 0, 14, .	2.8	0
258	Real-World Treatment Patterns and Survival Among Patients with Stage Iâ€“III, Non-Squamous, Non-Small Cell Lung Cancer Receiving Surgery as Primary Treatment. <i>Oncology and Therapy</i> , 0, , .	2.6	0